Rabies vaccine
Brand names: Rabipur, Verorab
Rabies vaccine is an inactivated viral vaccine used for pre-exposure immunisation of people at risk and as the cornerstone of post-exposure prophylaxis after potential rabies exposure.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It presents inactivated rabies virus antigen to the immune system, stimulating production of neutralising antibodies that provide active, durable protection against rabies infection.
Prescribing in practice
- After a significant exposure, prompt wound cleansing and a full vaccine course are essential, with rabies immunoglobulin added for unimmunised individuals, as rabies is almost invariably fatal once symptomatic.
- The number of doses and schedule differ between pre-exposure courses and post-exposure regimens and depend on prior immunisation and immune status per current guidance.
- It is administered by intramuscular injection and, for post-exposure prophylaxis, should never be withheld on account of pregnancy or breast-feeding.
Monitoring
Routine monitoring is not required, though antibody titre checks are used for certain occupationally exposed or immunosuppressed individuals.
Counselling the patient
- Complete every dose of the course on the dates given, as missing doses reduces protection.
- After any animal bite or scratch abroad, wash the wound thoroughly and seek medical advice at once.
- Tell the clinician if your immune system is weakened, as extra doses or antibody checks may be needed.
Evidence & guidelines
Rabies pre- and post-exposure vaccination schedules are set out in UK Health Security Agency (Green Book) and WHO guidance.
Reference: UKHSA Green Book Ch.27; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023